Empyrean Medical Systems Partners With Wide Code for Greater China Market Expansion

Empyrean Medical Systems, Inc., a prominent player in the medical device industry known for its cutting-edge radiation oncology technologies, has announced an exclusive long-term distribution agreement with Wide Code Industries Ltd. This strategic partnership aims to enhance Empyrean’s market presence across Mainland China, Hong Kong, and Macau, tapping into one of the world's fastest-expanding oncology markets.

Under this exclusive agreement, Wide Code will serve as the sole commercial distributor of Empyrean’s innovative products throughout the Greater China region. This not only involves the sales execution but also encompasses channel development and market expansion strategies while enabling future localization efforts tailored to the area's healthcare institutions. Although the exact financial terms of the partnership were not disclosed, both parties express strong optimism regarding the venture.

Kal Fishman, CEO of Empyrean Medical Systems, emphasized the significance of this agreement by stating that Greater China is a strategically crucial growth market for the company. However, entering this market requires a focused approach on local execution capabilities. The partnership with Wide Code allows Empyrean to penetrate this critical region efficiently, maintaining a disciplined operational focus and capital efficiency without the burden of large upfront investments.

The oncology market in China has witnessed substantial growth in recent years, driven by a rising prevalence of cancer, demographic shifts, and increased investments in hospital infrastructure. For international medical device companies like Empyrean, establishing exclusive regional partnerships has become a preferred strategy to accelerate market entry while minimizing the risks associated with execution and fixed costs.

Fishman further explained, "Our priority is to establish sustainable global growth, and this partnership is indicative of how we plan to scale our operations—by collaborating with established regional partners while maintaining a laser focus on our financial health."

Wide Code Industries has been a formidable player in the medical device sector for over 30 years in Greater China, and its CEO, Jordan Sun, conveyed strong confidence in this partnership. He suggested that the collaboration is more than just a distribution agreement; it is a long-term strategic alliance benefitting both companies as they navigate the demands of the local healthcare landscape.

According to Sun, there is a burgeoning and sustained demand for advanced oncology treatment technologies across Greater China. The innovative and scientific approach that Empyrean takes with its product offerings aligns perfectly with the requirements of local healthcare institutions striving to upgrade their treatment standards. He views this collaboration as laying a strong foundation for sustained growth in both companies, leveraging Wide Code’s extensive regional network and operational expertise.

Founded in 1990, Wide Code has built a remarkable reputation in partnering with well-known international brands, focusing in recent years on bringing advanced medical technologies, including radiation oncology and robotic-assisted medical devices, to the Greater China region. The company’s deep market presence, coupled with its professional capabilities, positions it as a strong partner for Empyrean.

Looking ahead, Empyrean sees the Asian market as pivotal to its long-term growth strategy. The company anticipates replicating similar successful partnership models in international markets, reinforcing its commitment to building a scalable and sustainable global commercial platform through focused and selective long-term partnerships.

About Empyrean Medical Systems, Inc.

Empyrean Medical Systems specializes in the development and commercialization of innovative radiation therapy solutions. Among its flagship products is the Magnetically Optimized Very High Energy Electron Therapy (MOVHEET) method, which promises enhanced precision, efficacy, and cost-effectiveness in cancer treatment while significantly reducing unwanted side effects. With a robust intellectual property portfolio, Empyrean is poised for significant revenue growth starting in 2026.

About Wide Code Industrial Group

Wide Code Industrial Group, established in 1990, stands as a reputable medical device company focused on the Greater China market, leveraging over 30 years of experience and a solid network across the region. The Group has effectively commercialized various products for international medical technology brands and aims to introduce localized advanced technologies in fields like radiation oncology.